On Wednesday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Angie’s List (NASDAQ:ANGI), Cirrus Logic, (NASDAQ:CRUS), Kite Pharma (NASDAQ:KITE), Pacira Pharmaceuticals (NASDAQ:PCRX)
Angie’s List Inc (NASDAQ:ANGI) has surpassed 200,000 paid members in a single market.
the Indianapolis-headquartered company disclosed that this week its New York City paid household membership exceeded the 200,000 milestone. New York City has ranked as the company’s largest market since 2011 followed by Washington DC, Los Angeles, Chicago and Boston. More than three million households across the country are members of Angie’s List.
Angie’s List Inc (NASDAQ:ANGI) fell -3.58%, and closed at $5.66. The stock has the beta value of 1.10, and its volatility for the week is 5.47%, while for the month it is 4.58%. The company has the market capitalization of $343.49 million. The company holds the book value per share of -0.38, whereas cash per share is 1.10. Price to sale ratio is 1.05. Analysts mean recommendation for the stock is said to be 2.80 (where 1=Buy, 5=sale).
Angie’s List Inc (ANGI) works a local services marketplace and consumer review site in the United States. The company offers marketplace to research, shop for, and purchase local services for home, health, and automotive service needs.
Formerly On March 26, 2015 Cirrus Logic, Inc. (NASDAQ:CRUS) disclosed that Alex Davern has been named to the company’s Board of Directors. Davern serves as executive vice president, chief financial officer and treasurer at National Instruments. Prior to joining National Instruments in 1994, Davern worked for Pricewaterhouse-Coopers in Europe and the United States. Davern holds a bachelor’s degree in business studies and a post-graduate diploma in professional accounting from University College Dublin.
Cirrus Logic, Inc. (NASDAQ:CRUS) decreased -3.55%, and closed at $32.08,. The company holds the market capitalization of $2.09 billion. For the last twelve months, the stock was able to keep return on equity at 6.90%, while return on assets at 5.10%, in -3.16 to its return on investment at 16.80%. Its 20-day moving average decreased -3.16%, below 50-day moving average of 6.16%, below 200-day moving average of 33.69% from the latest market price of $32.08. The mean recommendation of analysts for this stock is 2.30. (Where 1=Buy, 5=Sale).
Cirrus Logic, Inc. (CRUS) a fabless semiconductor company, develops analog and mixed-signal integrated circuits (ICs) for a range of consumer and industrial markets. The company offers audio products, including analog-to-digital converters (ADCs), digital-to-analog converters (DACs), codecs, digital interface ICs, volume controls, adaptive noise cancelling circuits, and amplifiers, as well as audio digital signal processors.
Formerly On March 26, 2015 Kite Pharma Inc (NASDAQ:KITE) a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, proclaimed fiscal-year and fourth quarter 2014 financial results for the period ended December 31, 2014. 2014 was a transformative year for Kite, marked by achieving several key corporate and clinical milestones,” said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. “In addition to our successful IPO and follow-on offering, we expanded our management team with world-class talent, filed our first investigational new drug application (IND) for our lead product candidate KTE-C19, and entered into a major research collaboration with Amgen.” Dr. Belldegrun continued, “More recently, we expanded our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) and completed an acquisition of T-Cell Factory B.V. (TCF(TM)), which together provide Kite with a platform for discovering and advancing T cell receptor (TCR) product candidates. We believe these key events will further drive the expansion of both our chimeric antigen receptor (CAR) and TCR portfolio.
Kite Pharma Inc (NASDAQ:KITE) declined -3.48%, and closed at $55.67. The company has the market capitalization of $2.45 billion. On the other hand the stock’s volatility for the week is 8.13%, and for the month is 6.85%. The stock’s price to book ratio is $11.05. Analyst’s mean recommendation regarding this stock is 1.40. (Where 1=Buy, 5=Sale).
Kite Pharma Inc (KITE) a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX)’s shares picked down -3.48%, and closed at $85.76. The stock volatility for the week is 4.58%, while for the month remained 4.18%. The company holds consensus target price of $119.50.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.39 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 79.80% and Annual EPS growth for the past 5 years is considered as 26.70%.
The mean recommendation of analysts for this stock is 1.90. (Where 1=Buy, 5=Sale).
Pacira Pharmaceuticals Inc (PCRX) a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products mainly for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
